Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. - sprookjes - yvandenbroek - TriplyDB

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

http://www.wikidata.org/entity/Q37616946

about

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies.Emerging drugs and therapeutics for systemic sclerosis.Epidemiology and treatment of pulmonary arterial hypertension.Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects.Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy

P2860

Q37538076-F1344289-ED28-4B46-B97E-47FBB65A0404 Q38998611-2C88C9C3-6DA2-4E77-9C33-0899021CEA31 Q39359218-8024E806-0FB3-47DD-AA70-A5FBDF9366F2 Q41356862-EC7154D0-DF08-422A-A757-AFE455A01204 Q47570643-12FE52E4-F646-48AD-80BE-783EA21E1D8B Q47845345-F089C46F-F6EF-43AD-8C2D-E31771F46A13 Q53835859-C933CCA5-0F40-434D-B80E-98A15B8C3C9F Q58705720-A5B3568A-7365-4C5D-AF96-A82324C253F5

P2860

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

http://www.wikidata.org/entity/Q37616946

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Riociguat for the treatment of ...... ts from PATENT-1 and PATENT-2.

@en

Riociguat for the treatment of ...... ts from PATENT-1 and PATENT-2.

@nl

type

label

Riociguat for the treatment of ...... ts from PATENT-1 and PATENT-2.

@en

Riociguat for the treatment of ...... ts from PATENT-1 and PATENT-2.

@nl

prefLabel

Riociguat for the treatment of ...... ts from PATENT-1 and PATENT-2.

@en

Riociguat for the treatment of ...... ts from PATENT-1 and PATENT-2.

@nl

P1433

Q37616946-0208BC9D-5404-464B-9232-5B53A205FDC6

P1476

Q37616946-D1EF098E-5672-4E44-97FB-95E868D68714

P2093

Q37616946-1C9C3470-38C3-433B-BAE8-AB92C6699658

Q37616946-323FE563-84B4-42F0-A2E6-78EEA674BDAF

Q37616946-3E4093DB-66F5-414E-96B2-7D6D3D5C09AB

Q37616946-5B6AC77E-FBC1-408C-81CC-5A2E9E0BFE23

Q37616946-83303A3C-3E7F-4D8E-A53F-8D22719672EB

Q37616946-D067186F-1C5F-4B91-B9E2-D380CB17B722

Q37616946-D639F3E2-CB44-4D71-8463-A5152BA351B6

P2860

Q37616946-169B3EF0-9F08-4E53-8EAE-DD952A1D6D55

Q37616946-36D78013-F029-4670-A29B-BF31EC67E701

Q37616946-45C55139-B511-4F01-943D-E717745EF320

Q37616946-5615B31E-78C6-44C4-8478-105175D13F57

Q37616946-6C1F524A-4DBC-42C6-817F-5B4FA7FCC9A9

Q37616946-715A9EBF-FD06-484C-B0A6-DF2519AB211A

Q37616946-7C91598B-7803-49AE-B8EA-FF57AB48F510

Q37616946-7F13CC76-B937-4CD3-9EAB-C3B66E8873E6

Q37616946-81D7896D-E838-49ED-80C5-C3AFC2CF4D9B

Q37616946-87C0FAAD-1666-4B37-8F73-6DBF43E41DC4

P304

Q37616946-EA5AF28A-100D-42AF-8F0A-77D43A60D319

P31

Q37616946-B088080C-1F83-4071-A2CE-1010EE972258

P356

Q37616946-E568790E-5C05-4D43-92FC-A424968FE303

P407

Q37616946-C505673B-B961-4593-8B25-F29683A07A3B

P433

Q37616946-754BB229-2614-423E-A4F3-C99F60196078

P478

Q37616946-21DA8608-CE90-475B-AE9C-D1990C8469A4

P50

Q37616946-2F27E7C7-20ED-4B8E-BDC6-DD293FDE1E8E

Q37616946-50BBE426-98CE-4BAB-880B-7B22B879AF87

Q37616946-68F1A15C-04C9-457C-BBD7-FF10250F5962

Q37616946-FF010DDC-BEC2-4D2C-9417-FA2B12FEFFFD

P577

Q37616946-A03BB4E7-71BC-4DA3-81E0-73AB745359B7

P698

Q37616946-1B202D37-A238-4847-8102-7C0DA55C398C

P921

Q37616946-BA424F0A-E5E1-459C-8DF9-62B04E1DD051

Q37616946-F21626A8-FCA7-44ED-BB69-288BD125AA26

P932

Q37616946-1BC33DAB-D100-44E2-9A34-2D23EA2D5398

P356

ANNRHEUMDIS-2015-209087

P1433

Annals of the Rheumatic Diseases

P1476

Riociguat for the treatment of ...... ts from PATENT-1 and PATENT-2.

@en

P2093

Annette Boeckenhoff

http://www.w3.org/2001/XMLSchema#string

Christian Meier

http://www.w3.org/2001/XMLSchema#string

Christopher P Denton

http://www.w3.org/2001/XMLSchema#string

Hossein-Ardeschir Ghofrani

http://www.w3.org/2001/XMLSchema#string

J Gerry Coghlan

http://www.w3.org/2001/XMLSchema#string

Janethe de Oliveira Pena

http://www.w3.org/2001/XMLSchema#string

Jian-Guo He

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats

Riociguat for the treatment of pulmonary arterial hypertension.

Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.

Pulmonary arterial hypertension in connective tissue diseases.

Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension

Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

P304

422-426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2015-209087

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Riemekasten

Friedrich Grimminger

Carmine Dario Vizza

P577

2016-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27457511

http://www.w3.org/2001/XMLSchema#string

P921

connective tissue

arterial hypertension

P932

5284330

http://www.w3.org/2001/XMLSchema#string